Asset Details
Do you wish to reserve the book?
Reduced intensity conditioning prior to allogeneic stem cell transplantation in first complete remission is effective in patients with acute myeloid leukemia and an intermediate-risk karyotype
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Reduced intensity conditioning prior to allogeneic stem cell transplantation in first complete remission is effective in patients with acute myeloid leukemia and an intermediate-risk karyotype
Do you wish to request the book?
Reduced intensity conditioning prior to allogeneic stem cell transplantation in first complete remission is effective in patients with acute myeloid leukemia and an intermediate-risk karyotype
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Reduced intensity conditioning prior to allogeneic stem cell transplantation in first complete remission is effective in patients with acute myeloid leukemia and an intermediate-risk karyotype
2010
Overview
To evaluate the efficacy of reduced intensity conditioning (RIC) prior to allogeneic stem cell transplantation (alloSCT) in patients with acute myeloid leukemia (AML) in first complete remission (CR1), we retrospectively analyzed the outcome of 93 consecutive patients transplanted at our institution either following RIC (
n
= 37) or standard myeloablative conditioning (MAC) (
n
= 56) between 1999 and 2007. Projected overall survival (OS) or disease-free survival (DFS) for all patients at 1, 2, and 5 years was 78 or 70%, 65 or 57%, and 61 or 53% in the RIC group versus 73 or 70%, 68 or 62%, and 56 or 54% in the standard MAC group. In the subgroup of patients with an intermediate-risk karyotype projected OS at 1, 2, and 5 years was 86, 68, and 68% following RIC (
n
= 21) or 75, 69, and 66% following standard MAC (
n
= 36). Relapse or treatment-related mortality (TRM) was 15 or 17% (RIC group) and 26 or 14% (standard MAC group). Taken together, these data suggest that RIC-alloSCT may induce stable remissions in patients with AML transplanted in CR1. In particular, patients with an intermediate-risk karyotype ineligible to transplantation following standard MAC may benefit from RIC-alloSCT in CR1 at a low TRM.
Publisher
Springer Japan,Springer,Springer Nature B.V
Subject
/ Adult
/ Aged
/ Allogeneic stem cell transplantation
/ Biological and medical sciences
/ Cyclosporine - administration & dosage
/ Female
/ Graft vs Host Disease - drug therapy
/ Graft vs Host Disease - prevention & control
/ Hematologic and hematopoietic diseases
/ Humans
/ Immunosuppressive Agents - administration & dosage
/ Leukemia, Myeloid, Acute - genetics
/ Leukemia, Myeloid, Acute - mortality
/ Leukemia, Myeloid, Acute - therapy
/ Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis
/ Male
/ Medicine
/ Mycophenolic Acid - administration & dosage
/ Mycophenolic Acid - analogs & derivatives
/ Oncology
/ Reduced intensity conditioning
/ Stem Cell Transplantation - methods
